ng] Life Sciences Intellectual Property Review: "Gilead to face HIV antitrust claims," Rory O'Neill, March 05, 2020, 11:30 AM Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw o

invitation. Miami/Fort Lauderdale Area I Executive Office Industry View Profile Send a Message See All Hope Abel, Sr Therapeutic Specialist at Gilead Sciences Connect EFTA_R1_00439434 EFTA01963385 Manny Cohen, President at D I T INC Connect COMPANIES IN NETWORK Gilead Sciences Follow Company This

Classification: Public Gilead Sciences (Buy, CP: $82.02, TP: $132.00, GILD.OQ, Robyn Karnauskas) 4Q13 update: light taxes create more leverage for Sovaldi 4Q13 product revenues beat cons

Deutsche Bank Markets Research Rating Buy North Anterica United States Health Care Biotechnology Company Gilead Sciences Alert Re...ty s GILD.00 4. enOn Tgte; GILD US NMS GILD Atripla recall is NOT an issue - DB thoughts post mgmt convo We have gotten many qu

4 09:38 AM From: EVS EquityFocus/db/dbcom@DBEM=A To: Date: 02/05/2014 05:01 AM Subject: DB: GILD.OQ - Robyn Karnauska= Classification: Public Gilead Sciences (Buy, CP: $82.02, TP: $132.00, GILD.OQ, Robyn Karnauskas)</=> 4Q13 update: light taxes create more leverage for Sovaldi 4Q13 product revenues beat

om: EVS EquityFocus/db/dbcom=DBEMEA To: Date: 02/05/2014 05:01 AM Subject: DB: GILD.OQ - Robyn Karnauskas Classification: Public font size=3> Gilead Sciences (Buy, CP: $82.02, TP: $132.00, GILD.0Q, Robyn Karnauskas)</=> 4Q13 update: light taxes create more leverage for Sovaldi 4Q13 product revenues beat